Health resource use and costs of symptomatic knee and/or hip osteoarthritis

Autor: Hamza Achit, A.-C. Rat, C. Gard, Jean-Hugues Salmon, Damien Jolly, Bruno Fautrel, Francis Guillemin, W. Ngueyon-Sime
Přispěvatelé: Service de Rhumatologie [Reims], Centre Hospitalier Universitaire de Reims (CHU Reims), Service de Rhumatologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Maladies chroniques, santé perçue, et processus d'adaptation (APEMAC), Université de Lorraine (UL), Centre d'investigation clinique - Epidémiologie clinique [Nancy] (CIC-EC), Centre d'investigation clinique [Nancy] (CIC), Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Vieillissement, Fragilité (VIEFRA - EA 3797), Université de Reims Champagne-Ardenne (URCA), AP-HP Hôpital universitaire Robert-Debré [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de rhumatologie [CHU Pitié Salpêtrière] (GRC-08 EEMOIS), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Hôpital Robert Debré, Hôpital Robert Debré-Centre Hospitalier Universitaire de Reims (CHU Reims), Salmon, Jean-Hugues
Jazyk: angličtina
Rok vydání: 2019
Předmět:
Adult
Male
medicine.medical_specialty
Total cost
Arthroplasty
Replacement
Hip
Biomedical Engineering
Osteoarthritis
Osteoarthritis
Hip
03 medical and health sciences
Indirect costs
0302 clinical medicine
Rheumatology
Prosthetic surgery
medicine
Hip osteoarthritis
Humans
Orthopedics and Sports Medicine
Knee
030212 general & internal medicine
Arthroplasty
Replacement
Knee
health care economics and organizations
Aged
030203 arthritis & rheumatology
[SDV.MHEP.RSOA] Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system
Hip
business.industry
Health resource
Health Care Costs
Health resources
Middle Aged
Osteoarthritis
Knee
Patient Acceptance of Health Care
medicine.disease
3. Good health
Costs
[SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system
Multicenter study
[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie
Cohort
Physical therapy
Female
[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie
France
business
Zdroj: Osteoarthritis and Cartilage
Osteoarthritis and Cartilage, Elsevier, 2019, 27 (7), pp.1011-1017. ⟨10.1016/j.joca.2019.03.005⟩
ISSN: 1063-4584
1522-9653
DOI: 10.1016/j.joca.2019.03.005⟩
Popis: International audience; Background: Data on the economic consequences of hip and knee osteoarthritis (OA) are scarce. We aimed to estimate the annual direct and indirect costs for patients followed for hip and/or knee OA in the Knee and Hip Osteoarthritis Long term Assessment (KHOALA) cohort.Methods: The KHOALA cohort, set up from 2007 to 2009, is a French multicenter study of 878 individuals with symptomatic knee/hip OA who were 40e75 years old. Resources used were collected annually for 5 years. Costs were assigned by using official sources and expressed in 2018 euros per patient.Results: The mean annual total costs per patient over the 5-year study period were 2,180 ± 5,305V. The mean annual direct medical costs per patient were 2,120 ± 5,275V and mean annual indirect costs per patient 180 ± 1,735V for people of working age. Costs increased slightly over the study period. Drugs were the largest cost share, representing over 50% of all direct costs. However, the proportion attributable to OA drugs accounted for only 10.5% of drug costs. The second cost share was hospitalizations; hip and knee prosthetic surgery accounted for 27% of surgery hospitalization costs. Health professional visits were the third cost share, accounting for 3% of direct medical costs. The median costs induced could be as high as 2 billion V/year (IQR 0.7e4.3) in France.Conclusion: Hip and knee OA costs were substantial and increased over the study period in France. However, the costs attributable to OA represented only a small fraction of overall costs.
Databáze: OpenAIRE
Externí odkaz: